Sunday, February 9, 2025

CATEGORY

Gilead

Trodelvy Receives FDA’s Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer

Key TakeawaysTrodelvy's unique mechanism targets Trop-2, present in over 90% of small cell and breast cancers. Breakthrough Therapy Designation accelerates the drug's development...

Yescarta Achieves High Survival Rates in Refractory Lymphoma Patients at ASH

Key TakeawaysYescarta’s consistent survival rates suggest it remains a reliable option for second-line therapy in R/R LBCL. Improvements in managing CRS and ICANS...

Gilead’s Lenacapavir Shows 96% Efficacy in Preventing HIV Infections

Gilead Sciences has highlighted significant advancements in HIV prevention with the publication of its Phase 3 PURPOSE 2 trial results in the esteemed New...

Gilead Highlights Lenacapavir’s Success in Preventing HIV

Key TakeawaysTwice-yearly injections enhance adherence compared to daily oral medications. Lenacapavir's multi-stage mechanism provides robust protection against HIV. High efficacy rates support the...

Gilead Highlights Liver Disease Research at AASLD 2024

Gilead Sciences Inc. is set to showcase an impressive array of research findings at the 2024 Liver Meeting organized by the American Association for...

Gilead and Merck’s New HIV Treatment Regimen Shows Promising Results

Key TakeawaysGilead Sciences and Merck's investigational combination of islatravir and lenacapavir demonstrates comparable effectiveness to daily HIV treatments in maintaining viral suppression. The...

HIV Infections Significantly Reduced with Lenacapavir in Gilead’s Groundbreaking PURPOSE 2 Trial

Key TakeawaysLenacapavir demonstrated a 96% reduction in HIV infections, proving more effective than daily Truvada. The trial included a diverse participant base, enhancing...

Gilead Secures Future of HIV Prevention with Bold Royalty-Free Agreements for Lenacapavir in High-Risk Countries

Key TakeawaysGilead signs royalty-free agreements with six global manufacturers to produce low-cost versions of Lenacapavir for HIV prevention and treatment. The initiative targets...

HIV Prevention Expanded as Gilead Signs Licensing Agreements for Low-Cost Lenacapavir in Resource-Limited Countries

Key TakeawaysGilead has signed royalty-free licensing agreements with six generic manufacturers to produce low-cost versions of lenacapavir for HIV prevention in 120 high-incidence,...

HIV Treatment Breakthrough: Lenacapavir Reduces Infections by 96%, Surpassing Truvada in Twice-Yearly PrEP

Key TakeawaysLenacapavir demonstrated a 96% reduction in HIV infections compared to background HIV incidence in the Phase III PURPOSE 2 trial. Lenacapavir’s twice-yearly...

Cholangitis: Gilead’s Livdelzi Receives Accelerated FDA Approval for Primary Biliary Cholangitis (PBC)

Cholangitis, specifically primary biliary cholangitis (PBC), now has a promising new treatment option with the U.S. Food and Drug Administration (FDA) granting accelerated approval...

Gilead’s Twice-Yearly HIV Prevention Therapy Shows 100% Efficacy in Phase 3 Trial

Gilead Sciences, Inc. (Nasdaq: GILD) announced outstanding results from its pivotal Phase 3 PURPOSE 1 trial, which assessed the efficacy and safety of lenacapavir,...

Gilead and Elton John AIDS Foundation Expand HIV Efforts in Eastern Europe

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a significant five-year extension of their RADIAN®...

Patient Care Data Drives Kite Pharma’s CAR T Cell Therapy Advancements, Emphasizing Real-World Evidence

Healthcare innovations continue to reshape patient care, with recent advancements coming from Kite Pharma, a subsidiary of Gilead Sciences. Early last month, the company...

Promising Results for HIV Prevention: Gilead’s Lenacapavir Achieves 100% Efficacy

HIV prevention in cisgender women shows promising interim results from Gilead Sciences' Phase III PURPOSE 1 trial, which evaluates the efficacy of the twice-yearly...

Latest news